Ferran Fece de la Cruz

Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today @CD_AACR @MassGenBrigham @harvardmed #CorcoranLab #Rezatapopt #p53Y220C #PYNNACLE aacrjournals.org/cancerdiscover…

Hey @EMA_News and @Swissmedic_ Please act fast on this as well. Metastatic pancreatic cancer is a nasty disease with a median survival of 1 year, in many cases significantly less. > 90% of these patients are eligible for this drug, they don’t have a single day to lose!

🚨 One step closer to approval! 🚨 #Daraxonrasib #KRAS #pancsm

FYI: There is Access to KRAS drugs in international locations. Colorectal cancer KRAS G12V nine trials - US (7), China (3) , Japan, France, Spain, In our Facebook groups, we post about trial locations (there's one in Ireland!) (and expansions) and use #EUtrials to help patients find their options. Simple search on ctg clinicaltrials.gov/search?cond=Co… Use KRAShub.org for more options (e.g. solid tumor cancer trials, pan-KRAS and pan-RAS options).

🚨 New in @TheLancetOncol Dr. Seth Wander et al. share results from the investigator-initiated phase 1b TAKTIC trial evaluating safety & activity of ipatasertib (AKTi) + endocrine therapy, ± CDK4/6i, in HR+/HER2- metastatic #BreastCancer 🔗 doi.org/10.1016/S1470-…

Great to see the results from the #TAKTIC study reported today at @TheLancetOncol. Congrats Seth Wander, @maxwellRlloyd & colleagues! #Ipatasertib #bcsm @MGBResearchNews @MGBCI_BreastOnc @harvardmed AKT-targeted triplet therapy in advanced breast cancer ⬇️ sciencedirect.com/science/articl…

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma @Cancer_Cell @curecc @KRASKickers #KRAS cell.com/cancer-cell/fu…

Time goes by so slowly... @ASCO #Daraxonrasib #RASolute302 🗓 #May31

Preclinical data on RM-055...Am I having a hallucination? 🤯🤯🤯 @RevMedicines #AACR26 #KRAS #Hydrolysis

Did we ever see anything better than 11.1 mPFS in 2L NSCLC? Btw I believe $RVMD is on track to be the first one to take down the 14% CRC market too because: - Zoldon 2L NSCLC PFS > Soto/Ada 2L NSCLC PFS - Soto/Ada + Cetu/Pani in CRC approved G12C is just 3% of CRC, G12D is the most common KRAS mutation by a large margin in CRC

“It's a reason for optimism.” @DanaFarber's Andrew Aguirre, MD, PhD, discusses data released this week on the pancreatic cancer drug daraxonrasib, an oral pill that is a multi-selective RAS inhibitor. @DanaFarber_Hale Read more here: bit.ly/4tg1l7t

Rezatapopt (PC14586) generated rapid, durable responses in heavily pretreated patients with TP53 Y220C–mutated ovarian cancer, with ~44% ORR and consistent activity across subgroups in the phase 2 PYNNACLE trial 📊 Read more ➡️ onclive.com/view/rezatapop… #OvarianCancer #PrecisionOncology #TP53 #TargetedTherapy #Oncology #MedTwitter #SGO2026 @SGO_org #gynsm #ovca

"For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option." #Daraxonrasib #KRAS #pancsm statnews.com/2026/04/14/ben…

PYNNACLE phase II p53 reactivated against TP53 Y220Cm patients with platinum resistant #ovariancancer with ORR44% (1 radiographic CR). TP53 Y220C VAF decline seems to correlate to radiographic response! #SGOAM26 @SGO_org

Phase 3 RASolute 302 in pancreatic cancer patients clinically meaningful improvements in PFS and OS! 🤯 Daraxonrasib (oral RAS(ON) multi-selective) mOS 13.2m vs. chemotherapy mOS 6.7m!!! Looking forward to see all the data. @KRASKickers @PanCAN ir.revmed.com/news-releases/…

@SGO_org Although not in ovarian cancer, resistance mechanisms to rezatapopt have already been reported by @FerranFeceCruz and @AndreasVarkaris. An important paper to keep in mind as rezatapopt moves forward. @MassGenBrigham @harvardmed #CorcoranLab aacrjournals.org/cancerdiscover… #SGOAM26

The Moving Target: Cis-Mutation-Driven Resistance to p53-Y220C Reactivator. pubmed.ncbi.nlm.nih.gov/41918356/ #p53

Great commentary on our recent publication characterizing resistance to p53-Y220C reactivators @CD_AACR @MGBResearchNews aacrjournals.org/cancerdiscover…

A p53 reactivator in cancer would be a breakthrough, but the selection pressure to inactivate p53 is so strong, there'd always be concern about resistance The first clinical report on this just came out, which found resistance through second mutations in p53's DNA-binding domain, and mutations that prevent binding of Rezatapopt in the Y22OC pocket

🤯

This is a declaration of war 🤯